According to Gram Research analysis, women with pregnancy and lactation-associated osteoporosis can recover bone strength through multiple treatment approaches. A 2026 study of 59 Turkish women found that those receiving teriparatide showed 19.1% improvement in spine bone density early on versus 9.5% with calcium and vitamin D alone, but this difference disappeared by later follow-up visits. All treatment groups demonstrated substantial bone recovery over time, suggesting that even simpler treatments can be effective for this rare condition affecting young women.
A new study from Turkey followed 59 young women with pregnancy and lactation-associated osteoporosis, a rare condition where bones become weak during or after pregnancy. Researchers tracked how different treatments helped restore bone density over time. Women who received a bone-building medication called teriparatide showed faster early improvement in spine bone density compared to those taking only calcium and vitamin D supplements. However, by the second follow-up visit, all treatment groups showed similar improvements. The findings suggest that bones can recover well with various treatment approaches, but doctors still need more research to determine the best strategy for each patient.
Key Statistics
A 2026 cohort study of 59 women with pregnancy and lactation-associated osteoporosis found that 86.4% had vertebral fractures and 67.8% had multiple fractures, highlighting the severity of this rare condition in young women.
In a Turkish multicenter study of 59 women, those receiving teriparatide showed 19.1% improvement in lumbar spine bone density compared to 9.5% in the calcium and vitamin D group, a difference of 11.5 percentage points that was statistically significant early on.
A 2026 analysis of 59 women with pregnancy and lactation-associated osteoporosis found that the early advantage of teriparatide over calcium and vitamin D supplementation was no longer significant after adjusting for baseline bone density, age, body weight, and fracture history.
Across all treatment groups in a 59-woman cohort study, lumbar spine bone density improved significantly, and by the second follow-up visit, women receiving teriparatide showed similar bone density gains as those managed with calcium and vitamin D alone.
The Quick Take
- What they studied: How different bone-strengthening treatments work for young women who develop weak bones during pregnancy or while breastfeeding
- Who participated: 59 women with an average age of 29 years who had pregnancy and lactation-associated osteoporosis, recruited from 18 hospitals across Turkey
- Key finding: Women taking teriparatide (a bone-building injection) showed 19.1% improvement in spine bone density early on, compared to 9.5% for those taking calcium and vitamin D alone, but this difference disappeared by later follow-up visits
- What it means for you: If you develop weak bones during pregnancy or breastfeeding, multiple treatment options can help restore bone strength. While some medications work faster initially, all approaches showed meaningful recovery over time. Talk with your doctor about which option fits your situation best.
The Research Details
This was a retrospective cohort study, meaning researchers looked back at medical records from 59 women who had already been treated for pregnancy and lactation-associated osteoporosis across 18 different hospitals in Turkey. The women were divided into four groups based on their first-line treatment: 10 received bisphosphonates (a common bone-strengthening medication), 3 received denosumab (another bone-building drug), 22 received teriparatide (an injectable medication that stimulates bone formation), and 24 received only calcium and vitamin D supplements.
Researchers collected information about each woman’s age, weight, bone density measurements, fracture history, and how their bones responded to treatment over time. They specifically tracked bone density changes in three locations: the lower spine, the upper thighbone (femoral neck), and the entire hip area. The team measured bone density at the start of treatment and at follow-up visits to see which treatments produced the best results.
This study design is valuable because it shows what actually happens in real medical practice across multiple hospitals, rather than in a controlled laboratory setting. By following women over time and comparing different treatment approaches, researchers could identify which strategies work best for restoring bone strength in this specific group. Understanding real-world outcomes helps doctors make better treatment decisions for future patients.
This study has several strengths: it included patients from 18 different hospitals, which makes the findings more representative of actual practice, and it tracked bone density changes over time rather than just looking at one moment. However, the study has limitations worth noting. The sample size of 59 women is relatively small, and the study was retrospective, meaning researchers relied on existing medical records rather than following patients prospectively. The groups receiving different treatments were not randomly assigned, so differences between groups might reflect patient characteristics rather than medication effectiveness. The researchers did try to account for these differences through statistical adjustment, but this doesn’t completely eliminate the possibility of bias.
What the Results Show
All four treatment groups showed significant improvement in spine bone density during follow-up. Women receiving teriparatide demonstrated the fastest early improvement, with spine bone density increasing by 19.1% compared to 9.5% in the calcium and vitamin D group. This difference of 11.5 percentage points was statistically significant early on.
However, when researchers adjusted their analysis to account for differences in patients’ baseline bone density, age, body weight, and whether they had multiple spine fractures, the advantage of teriparatide disappeared. This suggests that the early benefit may have been due to differences in the types of patients receiving each treatment rather than the medication itself.
By the second follow-up visit, all treatment groups showed similar levels of bone density improvement, with no significant differences between groups. This indicates that even simpler treatments like calcium and vitamin D supplementation can lead to substantial bone recovery over time.
Total hip bone density improved significantly in both the teriparatide group and the calcium/vitamin D group, but not in the bisphosphonate or denosumab groups. Femoral neck bone density (the upper thighbone) improved significantly only in the teriparatide group. These findings suggest that different medications may affect different parts of the skeleton in different ways. The study also found that 86.4% of women had vertebral fractures (broken bones in the spine), and 67.8% had multiple fractures, highlighting how serious this condition can be.
This is one of the first large real-world studies examining treatment outcomes for pregnancy and lactation-associated osteoporosis. Previous research has been limited, with most knowledge coming from small case reports or expert opinion. This study provides valuable evidence that multiple treatment approaches can work, which aligns with current medical practice but hadn’t been systematically documented before. The finding that simpler treatments like calcium and vitamin D can produce meaningful bone recovery is reassuring and suggests that aggressive treatment isn’t always necessary.
The study’s main limitation is its small sample size of 59 women, which limits how confidently we can apply these findings to all women with this condition. The groups receiving different treatments were not randomly assigned, meaning sicker or healthier patients may have preferentially received certain medications. Although researchers tried to statistically adjust for these differences, this doesn’t completely eliminate bias. The study was retrospective, relying on existing medical records that may have incomplete information. Additionally, the study only included patients from Turkey, so results may not apply equally to other populations. Finally, the study didn’t include a control group of untreated women, so we can’t say whether any improvement would have occurred without treatment.
The Bottom Line
If you develop weak bones during pregnancy or breastfeeding, treatment can help restore bone strength. Starting with calcium and vitamin D supplementation is a reasonable first approach, as this study shows it produces meaningful improvement over time. If your bone density doesn’t improve adequately or you have multiple fractures, your doctor may recommend stronger medications like teriparatide, bisphosphonates, or denosumab. The choice should be individualized based on your specific situation, fracture risk, and preferences. These recommendations are based on moderate evidence from this real-world study, though more research is still needed.
This research is most relevant for women of childbearing age who develop weak bones during pregnancy or while breastfeeding. It’s also important for obstetricians, endocrinologists, and other doctors who care for these women. Women with a family history of osteoporosis or those who have experienced fractures during pregnancy should be especially aware of this condition. The findings are less directly applicable to men or to postmenopausal women with osteoporosis, whose condition has different causes.
Based on this study, you can expect to see measurable improvements in bone density within the first few months of treatment, with continued improvement over subsequent follow-up visits. The fastest improvements appeared in the first assessment period, though all groups continued to show gains. Most women in this study were followed for multiple visits over several months, suggesting that meaningful recovery takes time. Don’t expect overnight results, but consistent treatment should produce noticeable bone strengthening within a few months.
Frequently Asked Questions
Can bones recover from osteoporosis during pregnancy and breastfeeding?
Yes, according to a 2026 study of 59 women, bones can substantially recover with treatment. All treatment groups, including those taking only calcium and vitamin D, showed significant improvement in bone density over time, suggesting recovery is possible with various approaches.
What is the best treatment for pregnancy and lactation-associated osteoporosis?
Research shows multiple treatments work, but the optimal choice depends on individual factors. A 2026 study found teriparatide produced faster early improvement (19.1% versus 9.5%), but calcium and vitamin D alone also led to substantial recovery. Your doctor should personalize treatment based on fracture severity and your preferences.
How common are fractures in women with pregnancy-related bone loss?
Pregnancy and lactation-associated osteoporosis causes fractures in most affected women. A 2026 study of 59 women found 86.4% had spine fractures and 67.8% had multiple fractures, showing this condition can cause serious skeletal damage in young women.
How long does it take to see bone density improvement with treatment?
A 2026 study tracking 59 women found measurable improvements in bone density at early follow-up visits, with continued gains at later assessments. Most women showed meaningful recovery within several months of starting treatment, though individual timelines vary.
Is calcium and vitamin D enough to treat pregnancy-related osteoporosis?
A 2026 study of 59 women found that calcium and vitamin D supplementation alone produced substantial bone density improvement over time, with 9.5% lumbar spine improvement. However, stronger medications may be needed for women with severe fractures or inadequate response to supplements.
Want to Apply This Research?
- Track your calcium and vitamin D intake daily (target 1000-1200 mg calcium and 600-800 IU vitamin D), along with any bone-related symptoms like back pain or new fractures. Log medication adherence if taking bisphosphonates, denosumab, or teriparatide.
- Set daily reminders to take calcium and vitamin D supplements with meals. If prescribed teriparatide, schedule weekly injection reminders. Add weight-bearing exercises like walking or dancing for 30 minutes most days, as these strengthen bones. Avoid smoking and limit caffeine, which can weaken bones.
- Schedule bone density scans (DEXA scans) every 6 to 12 months to track improvement. Keep a symptom log noting any new pain, fractures, or concerns. Share results with your doctor at each visit to adjust treatment if needed. Track medication side effects and report any concerns promptly.
This article summarizes research findings and is not medical advice. Pregnancy and lactation-associated osteoporosis is a serious condition requiring professional medical evaluation and treatment. If you are pregnant, breastfeeding, or have experienced fractures, consult your obstetrician, endocrinologist, or primary care physician before starting any new treatment. Individual treatment decisions should be based on your specific medical history, bone density measurements, fracture risk, and other health factors. Do not stop or change prescribed medications without consulting your healthcare provider.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.